ASH and FDA Unveil New Recommendations to Guide Clinical Development of Sickle Cell Disease Therapies
Joint FDA/ASH Led Initiative Highlights Importance of Using Patient Reported Outcomes and Biomarkers in Clinical Trials to Advance SCD Therapies (WASHINGTON,... Continue Reading
GBT’s Oxbryta™ (voxelotor) tablets is approved for the treatment of sickle cell disease
Oxbryta™ (voxelotor) tablets Now Approved On behalf of GBT, we are happy to share that Oxbryta (pronounced ox-brye-ta) is now approved... Continue Reading